BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 1983412)

  • 1. Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs.
    Savarino V
    Ital J Gastroenterol; 1990; 22 Suppl 2():20-3. PubMed ID: 1983412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording.
    Savarino V; Mela GS; Zentilin P; Scalabrini P; Bonifacino G; Gambaro P; Celle G
    Digestion; 1989; 42(1):1-6. PubMed ID: 2568299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do anticholinergics interact with histamine H2 receptor antagonists on night intragastric acidity in active duodenal ulcer patients?
    Fiorucci S; Clausi GG; Farinelli M; Santucci L; Farroni F; Pelli MA; Morelli A
    Am J Gastroenterol; 1988 Dec; 83(12):1371-5. PubMed ID: 2904218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg.
    Savarino V; Mela GS; Zentilin P; Cutela P; Mele R; Celle G
    J Clin Pharmacol; 1993 Jan; 33(1):70-4. PubMed ID: 8429117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overnight comparable anacidity by standard large and half-single bedtime doses of H2 antagonists in duodenal ulcer patients: a clinical pharmacological study.
    Savarino V; Mela GS; Scalabrini P; Sumberaz A; Fera G; Zentilin P; Celle G
    Am J Gastroenterol; 1988 Sep; 83(9):917-22. PubMed ID: 2901220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of gastric acid rebound after stopping a successful short-term course of nizatidine in duodenal ulcer patients.
    Savarino V; Mela GS; Zentilin P; Sumberaz A; Bonifacino G; Celle G
    Am J Gastroenterol; 1991 Mar; 86(3):281-4. PubMed ID: 1671805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine.
    Dammann HG; Gottlieb WR; Walter TA; Dreyer M; Müller P; Simon B; Keohane P
    Hepatogastroenterology; 1986 Oct; 33(5):217-20. PubMed ID: 2879782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral famotidine on 24-hour intragastric acidity.
    Santana IA; Lanzon-Miller S; Pounder RE
    Postgrad Med J; 1986; 62 Suppl 2():39-42. PubMed ID: 2890150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous 24-hour intragastric pH monitoring in the evaluation of the effect of a nightly dose of famotidine, ranitidine and placebo on gastric acidity of patients with duodenal ulcer.
    Savarino V; Mela GS; Scalabrini P; Di Timoteo E; Magnolia MR; Celle G
    Digestion; 1987; 37(2):103-9. PubMed ID: 3305114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single morning and nightly doses of ranitidine 300 mg: an appraisal of their antisecretory effects by continuous pH monitoring.
    Savarino V; Mela GS; Zentilin P; Sumberaz A; Cutela P; Celle G
    Digestion; 1991; 48(3):141-8. PubMed ID: 1916034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acid secretion and acid suppression in pathogenesis and healing of peptic ulcer disease.
    Thomson AB
    Hepatogastroenterology; 1990 Jul; 37 Suppl 1():18-28. PubMed ID: 1976583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-four-hour intragastric pH-metry: H2-receptor antagonist restoration of nightly gastric spontaneous alkalinization in duodenal ulcer healing.
    Bianco A; Cagossi M; Piraccini R; Greco AV
    Riv Eur Sci Med Farmacol; 1992; 14(5):281-91. PubMed ID: 1364062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of an oral morning dose of nizatidine and ranitidine on gastric acid secretion in duodenal ulcer patients.
    Lazzaroni M; Bianchi Porro G
    Hepatogastroenterology; 1989 Dec; 36(6):490-3. PubMed ID: 2575571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single dose ranitidine: influence of the time of administration on gastric acidity in normal subjects and in patients with duodenal ulcer.
    Coppens JP; Warzee P; Schapira M; Fiasse R; Dive C
    Gastroenterol Clin Biol; 1988; 12(6-7):537-41. PubMed ID: 3417080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine.
    Fullarton GM; Macdonald AM; McColl KE
    Aliment Pharmacol Ther; 1991 Aug; 5(4):391-8. PubMed ID: 1685675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Random double-blind comparison of nizatidine, famotidine, ranitidine and placebo.
    McAllister JD; Moote CA; Sharpe MD; Manninen PH
    Can J Anaesth; 1990 May; 37(4 Pt 2):S22. PubMed ID: 1972914
    [No Abstract]   [Full Text] [Related]  

  • 17. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine.
    Nwokolo CU; Smith JT; Gavey C; Sawyerr A; Pounder RE
    Aliment Pharmacol Ther; 1990; 4 Suppl 1():29-45. PubMed ID: 1983345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the H2-antagonist niperotidine on intragastric acidity in healthy subjects undergoing 24-hour pH-monitoring.
    Palasciano G; Maggi V; Portincasa P
    Ital J Gastroenterol; 1990 Oct; 22(5):291-4. PubMed ID: 1983712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of acid suppression in H2-antagonist nonresponders.
    Savarino V; Mela GS; Zentilin P; Cutela P; Mele MR; Celle G
    Digestion; 1992; 51(4):185-92. PubMed ID: 1356863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the information obtained from continuous 24-hour gastric pH monitoring.
    Mela GS; Savarino V; Vigneri S
    Am J Gastroenterol; 1992 Aug; 87(8):961-6. PubMed ID: 1353661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.